Alkaline Phosphatase Kinetics Predict Metastasis among Prostate Cancer Patients Who Experience Relapse following Radical Prostatectomy

Table 2

Multivariable Cox proportional hazards analysis of distant metastasis-free survival.

Variable	Hazard Ratio (95% CI)	p-value
Age at RP^1(years)	0.99 (0.95, 1.04)	0.78
Time from RP to BCR^2(years)	0.92 (0.81, 1.04)	0.18
Neo- and/or Adjuvant Treatments Received
Yes vs. No	1.36 (0.69, 2.69)	0.38
Post-BCR^2 Salvage Treatment Received
HT Only vs. None	0.94 (0.45, 1.98)	0.87
XRT Only vs. None	0.47 (0.15, 1.41)	0.17
Multi-Treatmen vs. None	1.66 (0.73, 3.79)	0.23
APV^3Upper Quartiles (U/L-Y)
≥3.11 vs. <3.11	2.18 (1.23, 3.86)	0.008
PSADT^4(Months)
<10 vs. ≥10	2.01 (1.07, 3.78)	0.030
Race
African American vs. Caucasian American & Other	1.07 (0.54, 2.13)	0.84
Pathologic T stage
pT3-T4 vs. pT2	0.99 (0.47, 2.07)	0.97
Pathologic Gleason Sum
3+4 vs. ≤6	1.1 (0.53, 2.28)	0.81
4+3 vs. ≤6	0.91 (0.32, 2.58)	0.85
≥8 vs. ≤6	2.29 (1.03, 5.07)	0.042
Surgical Margin Status
Positive vs. Negative	1.08 (0.53, 2.19)	0.84

RP=radical prostatectomy.
BCR=biochemical recurrence.
APV=alkaline phosphatase velocity.
PSADT=PSA doubling time.
ultitreatment refers to combinations of XRT and HT.